Notably, our findings suggest that TGF-β1 staining should be considered alongside other prognostic markers for AML transformation, despite previous studies highlighting the predictive value of genetic factors, G-CSF, and ESA treatment. The gene discussed is CSF3; the disease is acute myeloid leukemia.